Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bcr-Abl inhibition as a modality of CML therapeutics.

× No keyword cloud information.

25 in total

1. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Authors: Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi Antero Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Journal: Blood Date: 2010-03-18 Impact factor: 22.113

Review 2. Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

Authors: Ferdinand Rombout; Leon Aarons; Mats Karlsson; Anthony Man; France Mentré; Peter Nygren; Amy Racine; Hans Schaefer; Jean-Louis Steimer; Iñaki Troconiz; Achiel van Peer
Journal: J Pharmacokinet Pharmacodyn Date: 2004-12 Impact factor: 2.745

Review 3. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors: Bertrand Rochat
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

Review 4. Ten things you should know about protein kinases: IUPHAR Review 14.

Authors: Doriano Fabbro; Sandra W Cowan-Jacob; Henrik Moebitz
Journal: Br J Pharmacol Date: 2015-03-24 Impact factor: 8.739

5. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).

Authors: Jiaxin Wu; Aoli Wang; Xixiang Li; Cheng Chen; Ziping Qi; Chen Hu; Wenliang Wang; Hong Wu; Tao Huang; Ming Zhao; Wenchao Wang; Zhenquan Hu; Qingwang Liu; Beilei Wang; Li Wang; Lili Li; Jian Ge; Tao Ren; Ruixiang Xia; Jing Liu; Qingsong Liu
Journal: Cancer Biol Ther Date: 2019-03-20 Impact factor: 4.742

Review 9. New names for old disciplines.

Authors: H Galjaard
Journal: J Inherit Metab Dis Date: 2002-05 Impact factor: 4.982

10. Unbiased identification of substrates of protein tyrosine phosphatase ptp-3 in C. elegans.

Authors: Christopher J Mitchell; Min-Sik Kim; Jun Zhong; Raja Sekhar Nirujogi; Anjun K Bose; Akhilesh Pandey
Journal: Mol Oncol Date: 2016-03-25 Impact factor: 6.603

Bcr-Abl inhibition as a modality of CML therapeutics.